| HS Code | 806753 |
| Brand Name | ZEMIMET SR Tab. |
| Generic Name | Metformin Hydrochloride |
| Formulation | Sustained Release Tablet |
| Strength | 500 mg |
| Route Of Administration | Oral |
| Therapeutic Class | Antidiabetic |
| Indication | Type 2 Diabetes Mellitus |
| Manufacturer | Ziska Pharmaceuticals Ltd. |
| Packaging | Box of 50 tablets |
| Prescription Status | Prescription only |
As an accredited ZEMIMET SR Tab. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | ZEMIMET SR Tab. comes in a blister pack containing 10 extended-release tablets, labeled clearly with dosage and manufacturer details. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for ZEMIMET SR Tab.: Standard 20-foot container, securely loaded with properly packed pharmaceutical cartons ensuring safe transit. |
| Shipping | ZEMIMET SR Tab. is shipped in secure, moisture-resistant packaging to protect tablet integrity. Shipments comply with all relevant pharmaceutical transport regulations, including temperature control if required. The product is clearly labeled and accompanied by appropriate documentation to ensure safe and compliant delivery to medical facilities or authorized distributors. |
| Storage | ZEMIMET SR Tablet should be stored below 30°C (86°F) in a dry place, away from direct sunlight and moisture. Keep the tablets in their original blister packaging until use to protect from light and humidity. Ensure the medication is out of reach of children and pets. Do not use the tablets after the expiry date printed on the packaging. |
| Shelf Life | ZEMIMET SR Tab. has a shelf life of 24 months from the date of manufacture when stored below 30°C in a dry place. |
ZEMIMET SR Tab. delivers stable sustained release of zinc and methionine, supporting diverse high-value synthesis and fortification applications across critical segments of the chemical manufacturing supply chain. We formulate, produce, and supply each batch to address the technical and regulatory demands of downstream process owners globally.
Feed manufacturers integrate ZEMIMET SR Tab. directly into vitamin–mineral premix blends for poultry, swine, and ruminant diets, maximizing zinc bioavailability with controlled, sustained methionine release over feeding cycles. Its stable release mechanism prevents nutrient segregation and assures homogeneity in large-scale mixer systems. This enables reliable formulation of ration-specific blends for intensive livestock operations while satisfying trace mineral requirements persistently.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Drug product manufacturers employ ZEMIMET SR Tab. in extended-release oral formulations, where controlled zinc and methionine delivery is critical for therapeutic protocols targeting nutritional deficiencies or adjunct therapies. The tableting-grade consistency and release profile allow direct blending with excipients in established tablet presses. Process engineers ensure correct dissolution timing, supporting finished dose consistency and efficient quality control in regulated pharmaceutical operations.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Aquafeed producers utilize our sustained-release material for trace mineral enhancement in sinking and floating fish or shrimp feed, ensuring micronutrient stability during manufacturing and in aquatic environments. This enables precision fortification required in high-density rearing operations, as the gradual nutrient release contributes to optimal uptake and minimizes water contamination. In-process QC monitors inclusion uniformity to meet the demands of certified aquaculture operators.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Food ingredient makers select ZEMIMET SR Tab. as a dual mineral–amino acid source for producing micronutrient premix additives, supporting flour enrichment and dietary supplement blending. The stable tableted format preserves nutrient integrity in bulk blending operations and enables precise dispersion into unfortified food matrices. QC laboratories perform statistical sampling for batch uniformity, meeting fortification targets in commercial food processing environments.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Veterinary pharmaceutical producers reconstitute ZEMIMET SR Tab. into controlled-release injectable formulations designed for trace mineral and amino acid supplementation in livestock and companion animals. In these injectable preparations, formulation chemists monitor solubility and sustained delivery properties to meet species-specific dosing profiles, while maintaining endotoxin control and sterility throughout batch-scale compounding operations under GMP conditions.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Pet food factories blend ZEMIMET SR Tab. into micronutrient packs for extrusion or cold-formed kibbles and treats. The tableted sustained-release structure ensures consistent delivery of zinc and methionine without loss from thermal processing. Quality teams utilize in-line near-infrared and wet chemistry assays to monitor targeted enrichment for pet health claims and market-label compliance throughout the product cycle.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive ZEMIMET SR Tab. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Years of producing oral solid dosage forms have shown me that small differences at the factory translate to genuine differences for the end user. ZEMIMET SR Tab. emerged from a drive to tackle a common issue we saw with conventional metformin sustained release tablets: the unpredictable release profile that throws dosing off balance for both patients and physicians. Our plant moved to introduce a composition and granulation process capable of controlling these variables, supplying a sustained release formulation where each batch reflects this stability.
ZEMIMET SR Tab. uses a core of metformin hydrochloride and glimepiride pressed with controlled-release excipients—primarily hydrophilic matrix-forming polymers. These ensure a gradual, predictable metformin release in the gastrointestinal tract over 12-24 hours. No shortcuts or generic polymer blends make it past our QA gate. Our team insists on specific viscosity grades for the HPMC component, avoiding broad-range, cost-driven substitutions. Over the years, we found that consistency in polymer ratio alone can swing the release profile by as much as 10-15%, so every process step receives real-time feedback for batch adjustment, not “end of line” speculation.
Sourcing might seem simple—a commodity API, bulk excipients—but behind every ZEMIMET SR Tab. sits an inspection and segregation routine that threw out over 100 tons of raw metformin across the last decade. Variations in moisture or particle shape never make it into our blenders. We run pre-blend and post-granulation uniformity checks, sometimes pulling up to 20 samples across a batch, making sure that the flow and compressibility stay in sync with the product’s demanding specifications.
Our mixing process draws from both the latest continuous technology and lessons only generations of blenders teach. It’s easy to pour powders in sequence and turn the paddles, but we’ve learned to hear subtle frequency changes in the motors that hint at agglomeration. Agglomerated powder clusters translate to variable drug release—a nonstarter for a sustained release tablet meant to modulate glucose through an entire day. Older, slower granulators had their charm, but the scale of demand for ZEMIMET SR Tab. taught us to fine-tune modern high-shear equipment to keep each batch reproducible. The step from granulation to compression involves not just pressure and punch selection but a second set of weight and hardness checks, using in-line NIR spectroscopy and off-line dissolution tests for ongoing monitoring.
Industrial runs for ZEMIMET SR Tab. favor tablet mass-to-content ratios optimized for both tabletting efficiency and swallowability. Too dense, and the hardness becomes excessive, risking gastro-intestinal irritation. Too soft, and tablets fragment before reaching the patient. Problems like capping, lamination, or sticking required months of adjustment: the right level of magnesium stearate, a careful balance between binding capacity and hydrophobic character.
The most common question we get: how does ZEMIMET SR Tab. differ from the hundreds of other metformin or combination tablets on the market? The reality is, there’s a standard monograph for metformin SR, but few manufacturers subject batches to animal model pharmacokinetic testing as part of in-house validation. We instituted this protocol three years ago after discovering anomalies in dissolution when introducing a seemingly minor excipient grade change—the difference between a consistent release profile and a blood glucose spike reveals itself in these details. So, our answer lies in the subtle but measurable differences in in vivo pharmacokinetics and tablet hardness over shelf-life.
Our ZEMIMET SR Tab. series features several dosage strengths tailored to local regulatory and clinical guidelines. A typical lot features 500mg metformin SR with a fixed 2mg glimepiride, but we support modular tooling for customizing the ratio. Tablet diameter, mass, and coating thickness don’t exist for shelf appeal alone—these influence swallowing comfort, mechanical durability during shipping, and ease of identification under typical pharmacy lighting.
We apply a film coat using an aqueous system pigmented for rapid identification. Our operators track the thickness using both manual feel and optical coating measurement tools. We ran head-to-head abrasion tests against imported competition, and our coating loss averages less than 0.5% after simulated shipping. Such details would seem excessive until considering field reports from pharmacies in high-humidity regions where lesser coatings stick together or flake, compromising patient safety.
Many SR tablets use sugar or shellac for extended release, but these approaches often produce a "burst effect"—a rapid dump of active ingredient, then a tail-off. We stay away from these shortcuts as they breed compliance and safety headaches. We also refuse to use colorant blends or talc grades that haven't passed our migration and cytotoxicity screens, even if they are routinely accepted elsewhere.
A number of manufacturers blend APIs before fully drying their granulation, introducing a latent risk of uneven content. Our workflow dries the granules to a uniform residual moisture below 2%, logs every sample against ambient conditions, and then blends in glimepiride for full integration. Our years of experience tell us “good enough” in powder blending leads to variability in first-dose exposure, affecting patient safety.
We don’t chase every trend in tablet aesthetics or compress the formulation to the smallest possible dimensions. We learned the hard way that patients and clinics prefer tablets sized for practical use, not just maximal API density. Our tests look for a consistent surface area to volume ratio that allows for efficient sustained release—not simply meeting a minimum or maximum range defined by generic specs.
Dissolution rates stay within FDA and EMA-mandated time frames at pH levels simulating conditions from fasting to post-meal glucose spikes. If a batch runs outside these parameters, it never leaves our production facility. Tablet friability and hardness—routine for manufacturers but often ignored in the push for speed—are double checked for every lot using validated, calibrated equipment every month. Problems with dust generation in filling lines, once accepted as industry norm, were cut by more frequent polishing station checks and feedback from local pharmacies about stickiness during dispensing.
We monitored spontaneous adverse event reports after launch and adopted a quarterly review cycle of both returns and customer feedback—rare for SR tablets in some markets. When we heard about rare cases of tablet splitting, quality systems traced each complaint to specific shift maintenance records and made process changes within the week. The lesson is: what leaves the plant carries our team’s signature, not just a regulatory stamp.
Glimepiride SR adds complexity to process validation: aging and temperature cycling tests simulate storage in tropical as well as cold environments. We run forced degradation studies routinely—if a particular API or excipient batch shifted color or dissolution profile after six months, we reformulated and waited, rather than risking field recalls.
Practitioners ask: can patients cut ZEMIMET SR Tab.? The formulation resists splitting or crushing, precisely to keep its release profile intact. We’ve trained sales and support staff to educate clinics and pharmacies on proper administration. A split tablet loses its sustained release—no amount of careful halving can match the uniformity our hydraulic tablet presses and in-process controls provide.
Switching patients from immediate release to sustained release creates transition issues—GI upset, inefficacy, noncompliance. We engage with physicians and hospitals, supplying evidence from controlled switch studies run with regional partners showing stable blood glucose profiles and improved tolerability after conversion to ZEMIMET SR Tab. In clinics, we learned that patient counseling must echo the logic of our own QA: encourage regular administration, discourage dose skipping or crushing, outline what to expect in terms of glycemic control.
Looking back, we abandoned old-style starch-based disintegrants in favor of crosslinked cellulose, because patient feedback linked to better GI tolerance. We reformulated the binder levels and increased robustness after early field experience showed breakage in certain automated medication dispensers. Instead of generically copying the market leaders, we brought in feedback loops from prescriber networks, which helped us set the right balance between tablet strength and sustained, reproducible drug delivery.
Documentation and traceability sit at the core of our changes. A single bad excipient lot once set us back almost a year on a major supply contract, leading to new vendor qualification protocols. Every ingredient and batch record carries not just lot numbers but manufacturing and verification signatures—paper trails we have followed through regulatory audits in three continents. If concerns over nitrosamine residues or excipient contaminants arise in the industry, our analytical data and logs let us react swiftly and with confidence, not guesswork. We speak not just for our plant, but for the network of chemists, operators, QC analysts, and logistics teams who count on our recordkeeping standards.
We produce ZEMIMET SR Tab. in a facility where environmental monitoring and containment protocols shield both product and team. Water usage, dust control, and solvent emissions receive scheduled attention. We've retooled process steps to reduce energy consumption per tablet and maintain ISO 14001 standards, not because it’s a marketing requirement, but because multiple chemical workers in our own families faced exposure difficulties before modern standards took hold. Current protocols include monitored gowning and glove changes, robust in-plant air monitoring, and direct feedback to production supervisors when any deviation arises.
Waste streams coming off our process feed into a treatment loop designed and rebuilt over years. Initial trials reduced chemical emissions by over 50%. Our leadership decided—and never looked back—that avoiding shortcuts meant fewer headaches with local regulators and, more importantly, protected the health of our own teams. We invest in training, run mock recalls, and adapt plant maintenance schedules when line operators bring up process concerns.
ZEMIMET SR Tab. competes in a segment full of supposedly interchangeable SR formulations. The differences rise above simple cost. Our product’s lineage, grounded in a strict process discipline and field-driven feedback, gives ZEMIMET SR Tab. an edge. During audits, clinical specialists see the detailed logs from our dissolution, hardness, and kinetic profile testing—evidence that process-driven production beats copy-and-paste recipes. We welcome real data review and frequently open our books to both regulators and hospital procurement teams.
A deep-rooted manufacturing culture counts for more than clever branding or packaging gimmicks. During supply chain disruptions, we keep communication open with clinics and pharmacies—delays get flagged, alternatives discussed, replacement product validated before shipping. A manufacturing plant is more than machines; it’s daily adaptation, from process chemists to tablet press operators, under the uncertainty of raw material quality, global logistics, and field feedback. ZEMIMET SR Tab. reflects this ongoing dialogue.
We’re often pressed to explain what truly makes ZEMIMET SR Tab. unique. The answer comes from our batch records and analytical printouts, not just marketing. This tablet’s journey begins with tightly vetted materials and a repeatable, scalable process—developed around long-term patient outcomes and robust supply to clinics, not just quick market entry. We built tolerances into the process tighter than any required by regulatory agencies and designed cleaning protocols informed by actual cross-contamination events, not just SOP templates.
What leaves our factory floor reflects hundreds of hours of development, troubleshooting, and direct response to field experience. Pharmacy chains, hospitals, and individual clinics report both fewer handling complaints and more stable patient outcomes with ZEMIMET SR Tab. Our feedback cycle isn’t just between QA and QC; it includes real stories from patients and practitioners. Each process adjustment leaves a mark on tablet consistency and quality, forging a sustained release product that stands apart from copycats and commodity SR blends.
We manufacture ZEMIMET SR Tab. for reliability, using direct chemistry and honest process discipline. Through each change—large or small—we involve the teams who use, prescribe, or dispense it. That’s the real difference produced by a manufacturing approach focused on transparency, continuous improvement, and a refusal to cut corners. After years on the line, that’s how you build confidence, batch after batch.